Basilea Pharmaceutica AG (BPMUF)
USD 52.83
(0.0%)
USD 52.83
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 19.2 Million CHF | 3.57% |
| 2022 | 18.54 Million CHF | 1462.17% |
| 2021 | 1.18 Million CHF | 114.44% |
| 2020 | -8.22 Million CHF | 52.2% |
| 2019 | -17.2 Million CHF | 28.62% |
| 2018 | -24.09 Million CHF | -70.45% |
| 2017 | -14.13 Million CHF | 67.79% |
| 2016 | -43.88 Million CHF | 29.95% |
| 2015 | -62.65 Million CHF | -49.79% |
| 2014 | -41.83 Million CHF | -25.67% |
| 2013 | -33.28 Million CHF | 29.4% |
| 2012 | -47.14 Million CHF | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 4.62 Million CHF | 126.16% |
| 2024 Q2 | 4.62 Million CHF | 0.0% |
| 2023 Q1 | 19.14 Million CHF | -30.61% |
| 2023 Q4 | -17.69 Million CHF | -116.1% |
| 2023 Q3 | -8.18 Million CHF | -122.19% |
| 2023 Q2 | 36.89 Million CHF | 92.76% |
| 2023 FY | 19.2 Million CHF | 3.57% |
| 2022 Q1 | -4.39 Million CHF | -126.6% |
| 2022 Q4 | 27.58 Million CHF | 86.34% |
| 2022 Q3 | 14.8 Million CHF | 263.73% |
| 2022 Q2 | -9.04 Million CHF | -105.64% |
| 2022 FY | 18.54 Million CHF | 1462.17% |
| 2021 Q2 | -15.35 Million CHF | -112.22% |
| 2021 Q4 | 16.52 Million CHF | 89.11% |
| 2021 FY | 1.18 Million CHF | 114.44% |
| 2021 Q1 | -7.23 Million CHF | 65.73% |
| 2021 Q3 | 8.73 Million CHF | 156.92% |
| 2020 FY | -8.22 Million CHF | 52.2% |
| 2020 Q1 | -629.5 Thousand CHF | 84.29% |
| 2020 Q4 | -21.11 Million CHF | -109.53% |
| 2020 Q2 | -2.14 Million CHF | -240.75% |
| 2020 Q3 | -10.07 Million CHF | -369.74% |
| 2019 FY | -17.2 Million CHF | 28.62% |
| 2019 Q4 | -4 Million CHF | -116.25% |
| 2019 Q1 | -5.98 Million CHF | -215.23% |
| 2019 Q3 | -1.85 Million CHF | 85.96% |
| 2019 Q2 | -13.19 Million CHF | -120.64% |
| 2018 FY | -24.09 Million CHF | -70.45% |
| 2018 Q3 | -1.89 Million CHF | 80.41% |
| 2018 Q2 | -9.68 Million CHF | 0.0% |
| 2018 Q1 | -9.68 Million CHF | -647.44% |
| 2018 Q4 | -1.89 Million CHF | 0.0% |
| 2017 Q1 | -8.83 Million CHF | 7.26% |
| 2017 Q4 | 1.76 Million CHF | 0.0% |
| 2017 FY | -14.13 Million CHF | 67.79% |
| 2017 Q2 | -8.83 Million CHF | 0.0% |
| 2017 Q3 | 1.76 Million CHF | 120.01% |
| 2016 Q2 | -12.41 Million CHF | 0.0% |
| 2016 Q3 | -9.52 Million CHF | 23.26% |
| 2016 Q4 | -9.52 Million CHF | 0.0% |
| 2016 FY | -43.88 Million CHF | 29.95% |
| 2016 Q1 | -12.41 Million CHF | 21.14% |
| 2015 FY | -62.65 Million CHF | -49.79% |
| 2015 Q3 | -15.74 Million CHF | -4.97% |
| 2015 Q2 | -14.99 Million CHF | 0.0% |
| 2015 Q1 | -14.99 Million CHF | -34.46% |
| 2015 Q4 | -15.74 Million CHF | 0.0% |
| 2014 Q2 | -9.76 Million CHF | 0.0% |
| 2014 FY | -41.83 Million CHF | -25.67% |
| 2014 Q4 | -11.15 Million CHF | 0.0% |
| 2014 Q3 | -11.15 Million CHF | -14.29% |
| 2014 Q1 | -9.76 Million CHF | -22.57% |
| 2013 Q3 | -7.96 Million CHF | 8.26% |
| 2013 FY | -33.28 Million CHF | 29.4% |
| 2013 Q4 | -7.96 Million CHF | 0.0% |
| 2013 Q2 | -8.68 Million CHF | 0.0% |
| 2013 Q1 | -8.68 Million CHF | -34.33% |
| 2012 FY | -47.14 Million CHF | 0.0% |
| 2012 Q3 | -6.46 Million CHF | 0.0% |
| 2012 Q4 | -6.46 Million CHF | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | 126.753% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | -290.758% |
| SQZ Biotechnologies Company | -75.82 Million USD | 125.328% |
| Evofem Biosciences, Inc. | -17.84 Million USD | 207.609% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | 76.537% |
| Mesoblast Limited | -84.14 Million USD | 122.823% |
| Propanc Biopharma, Inc. | -1.53 Million USD | 1350.286% |
| Genus plc | 6.4 Million USD | -200.078% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | -97.127% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | 2161.994% |
| Marizyme, Inc. | -34.08 Million USD | 156.342% |
| ContraFect Corporation | -56.88 Million USD | 133.759% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | 330.0% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | 521.65% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | 1469.838% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | 773.74% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | 798.151% |
| MultiCell Technologies, Inc. | -722.81 USD | 2657091.464% |
| Accustem Sciences Inc. | -3.74 Million USD | 612.623% |
| RVL Pharmaceuticals plc | -58.99 Million USD | 132.556% |
| EV Biologics, Inc. | -483.06 Thousand USD | 4075.68% |
| Q BioMed Inc. | -3.44 Million USD | 657.375% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | -442.514% |
| Neon Bloom, Inc. | -389.57 Thousand USD | 5029.794% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | 830.917% |
| Biomind Labs Inc. | -1 Million USD | 2002.233% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | -4.87 Million USD | 493.582% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | 388.883% |
| Skye Bioscience, Inc. | -13.67 Million USD | 240.472% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | 1066.786% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | 64219.257% |
| Arch Therapeutics, Inc. | -5.04 Million USD | 480.713% |
| IMV Inc. | -38.67 Million USD | 149.662% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 221.016% |
| Curative Biotechnology, Inc. | -1.93 Million USD | 1093.734% |
| GB Sciences, Inc. | -1.42 Million USD | 1451.98% |
| Alpha Cognition Inc. | -9.7 Million USD | 297.875% |
| HST Global, Inc. | -140.9 Thousand USD | 13729.557% |
| CSL Limited | 3.7 Billion USD | 99.481% |
| Halberd Corporation | -75.05 Thousand USD | 25689.607% |
| Enzolytics Inc. | -2.14 Million USD | 993.755% |
| Resverlogix Corp. | -12.74 Million USD | 250.639% |
| Affymax, Inc. | -15.04 Million USD | 227.642% |
| SYBLEU INC | -149.18 Thousand USD | 12973.71% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | 706.166% |
| argenx SE | -425.04 Million USD | 104.518% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | 134.599% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | 1939.559% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | 1316.003% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | 664.027% |
| AVAX Technologies, Inc. | 6.69 Million USD | -186.947% |
| Zenith Capital Corp. | -8.94 Million USD | 314.749% |
| Genscript Biotech Corporation | -415.79 Million USD | 104.619% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | 110340.514% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | 882.18% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | 11297.628% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | 134.936% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | 761.956% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | 2051.623% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | 1130.107% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | -1.25 Million USD | 1629.061% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | 1057.971% |
| BioStem Technologies, Inc. | -7.77 Million USD | 346.884% |
| ONE Bio Corp. | 13.68 Million USD | -40.372% |
| Reve Technologies, Inc. | -181.48 Thousand USD | 10682.142% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | 1538.112% |
| Wesana Health Holdings Inc. | -1.12 Million USD | 1807.254% |
| Agentix Corp. | -1.37 Million USD | 1500.03% |
| LadRx Corporation | -3.82 Million USD | 602.272% |
| Cell Source, Inc. | -4.32 Million USD | 544.011% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | 4722.376% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | 2895.691% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | 2895.691% |
| NovAccess Global Inc. | -2.46 Million USD | 878.552% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | 757.831% |
| Itoco Inc. | -919.14 Thousand USD | 2189.453% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | 553.118% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | 1816.265% |
| Kadimastem Ltd | -3.04 Million USD | 731.691% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | 7437.827% |
| CytoDyn Inc. | -18.05 Million USD | 206.352% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | 76401.152% |
| Mobile Lads Corp. | -554.55 Thousand USD | 3563.168% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | 8826.452% |
| Qrons Inc. | -643.67 Thousand USD | 3083.639% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | 3500.782% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | -2.22 Million USD | 961.257% |
| Rebus Holdings, Inc. | -664 Thousand USD | 2992.319% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | 1157.358% |
| International Stem Cell Corporation | -663 Thousand USD | 2996.682% |
| Bioxytran, Inc. | -3.82 Million USD | 602.729% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | 36583.663% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | 94519.862% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | -36.26 Million USD | 152.956% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | 1286.959% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | -735.83 Thousand USD | 2709.96% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | 717.326% |
| Neutra Corp. | -229.48 Thousand USD | 8468.702% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | 209.499% |
| PureTech Health plc | -146.19 Million USD | 113.136% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | 189.362% |
| IXICO plc | -1.43 Million USD | 1436.465% |
| IntelGenx Technologies Corp. | -9.49 Million USD | 302.35% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 115.767% |
| CSL Limited | 3.81 Billion USD | 99.496% |
| Cellectis S.A. | -108.85 Million USD | 117.642% |